Treatment with TLR4 antagonists has consistently resulted in reduced cytokine and chemokine production and mitigated disease symptoms in small animal models of IAV, EBOV, and DENV infections [12, 19, 25, 28, 29], clearly identifying a role for TLR4 activation in the pathogenesis of these viral diseases. Here, TLR4 is linked to viral load.